

NEW ORLEANS, LOUISIANA, 28 OCT. — 1 NOV. 2018



MMV & PARTNERS @ ASTMH 2018

67th Annual Meeting
Sheraton New Orleans
and New Orleans Marriott



Defeating Malaria Together

MMV 
Medicines for Malaria Venture

Symposium 10

Marriott, Mardi Gras EFGH, 3rd floor
Monday, 29 Oct., 8.00 am – 9.45 am

Building a combination platform for new antimalarial combination therapies

Chair: **Jörg J. Möhrle**, MMV, Switzerland

Co-Chair: **James McCarthy**, QIMR Berghofer Medical Research Institute, Australia

Speakers and topics:

- Developing a combination tool for *in silico* assessment of antimalarial drug partnering, **Nicole Andenmatten**, MMV, Switzerland
- Combination studies in *P. falciparum* infected, humanized SCID mice, **Inigo Angulo-Barturen**, The Art of Discovery (TAD), Spain
- Characterisation of new antimalarial combinations in induced blood stage malaria studies, **James McCarthy**, QIMR Berghofer Medical Research Institute, Australia
- Model-informed drug development for antimalarial combination therapies, **Ping Zhao**, Bill & Melinda Gates Foundation, USA

Scientific session 59

Marriott, La Galerie, 4/5/6, 2nd floor
Tuesday, 30 Oct., 8.00 am – 9.45 am

Malaria: pre-clinical and clinical drug development tools, novel approaches and new candidates

Co-Chair: **Francisco-Javier Gamo**, DDW, GlaxoSmithKline, Spain

Co-Chair: **Caroline Ng**, University of Nebraska Medical Center, USA

- 736** A human 3D cell-based platform for drug discovery targeting *Plasmodium* hepatic infection, **Catarina Brito**, iBET, Portugal
- 737** Proteasome inhibitor-based combination therapy potently inhibits artemisinin-resistant *Plasmodium falciparum*, **Caroline L. Ng**, University of Nebraska Medical Center, USA
- 738** Antimalarial pyrrolidinamides fast-acting compounds with a novel mode of action, **Laura M. Sanz**, GlaxoSmithKline, Spain
- 739** A randomized controlled trial comparing parasite clearance profiles after single dose artesunate among subjects experimentally infected with artemisinin-resistant or artemisinin-sensitive *Plasmodium falciparum* parasites, **Maria Rebelo**, QIMR Berghofer Medical Research Institute, Australia, MMV co-authors: Stephan Chalon and Jörg J. Möhrle
- 740** SJ733, An oral inhibitor of PFATP4 combined with a pharmacokinetic enhancer (CYP3A inhibitor): a novel approach in antimalarial drug development, **Aditya H. Gaur**, St. Jude Children's Research Hospital, USA, MMV co-authors: Andrew Slade and Stephan Chalon
- 741** KAF156 and LUM-SDF combination phase 2 study pharmacokinetic run-in cohort results, **Cornelis Winnips**, Novartis, Switzerland, MMV co-author: Sophie Biguenet
- 742** Pharmacogenetics of the IVERMAL Trial: human metabolic genes and mosquito mortality response to high-dose ivermectin co-administered with dihydroartemisinin-piperazine, **Menno R. Smit**, Liverpool School of Tropical Medicine, UK

Symposium 145

Sheraton, Rodrigue Gallery, 1st floor
Wednesday, 31 Oct., 4.00 pm – 5.45 pm

Supporting quality and child-friendly malaria interventions

Chair: **Pierre Hugo**, MMV, Switzerland

Co-Chair: **Martin de Smet**, Médecins Sans Frontières, Belgium

Speakers and topics:

- Ensuring a conducive environment for the introduction of quality, child-friendly medication, **Suzanne Hill**, WHO, Switzerland
- Reducing the malaria burden in community settings: synergism across varying transmission settings, **Elizabeth Chizema**, Ministry of Health, Zambia
- Management of severe malaria cases: learnings and challenges from the field, **Manuel Hetzel**, Swiss Tropical and Public Health Institute, Switzerland
- Severe malaria rapid assessments: knowledge, attitudes and practices, **Tendayi Kureya**, Development Data, Zimbabwe



Poster sessions

Marriott, Grand Ballroom, 3rd floor
Monday, 29 Oct., 12.00 pm – 1.45 pm

Poster Session A: Presentations and light lunch

- 302 Antimalarial pantothenamide metabolites target acetyl-CoA synthesis in *Plasmodium falciparum*, **Koen Dechering**, TropiQ Health Sciences, Netherlands, MMV co-author: Brice Campo
- LB-5058 Proguanil- old drugs new tricks, **Kathy Andrews**, Griffith University, Australia, MMV co-author: Jeremy Burrows

Marriott, Grand Ballroom, 3rd floor
Tuesday, 30 Oct., 12.00 pm – 1.45 pm

Poster Session B: Presentations and light lunch

- 996 The *ex vivo* growth profile of artemisinin-resistant parasites after artesunate treatment in the induced blood stage malaria model, **Maria Rebelo**, QIMR Berghofer Medical Research Institute, Australia, MMV co-author: Jörg J. Möhrle
- LB-5232 Discovery of new drug leads for malaria chemoprevention, **Katherine Andrews**, Griffith University, Australia, MMV co-author: Jeremy Burrows

Marriott, Grand Ballroom, 3rd floor
Wednesday, 31 Oct., 12.00 pm – 1.45 pm

Poster Session C: Presentations and light lunch

- LB-5534 Pregnancy outcomes in women exposed to dihydroartemisinin-piperaquine during the first trimester of pregnancy in Indonesia – a retrospective record linkage study, **Rukhsana Ahmed**, Liverpool School of Tropical Medicine, UK, MMV co-author: André-Marie Tchouatieu
- 1703 Drug sensitivities and mechanisms of resistance in Ugandan *Plasmodium falciparum* isolates to lead antimalarials in the Medicines for Malaria Venture development pipeline, **Stephanie A. Rasmussen**, Dominican University of California, USA, MMV co-author: Benjamin Blasco
- 1704 Identification of a dual liver-asexual stage antimalarial targeting PfDHODH, **Amanda K. Lukens**, The Broad Institute, USA, MMV co-authors: Brice Campo, Jeremy Burrows and Melanie Rouillier
- 1734 Impact of CYP2D6 on primaquine and tafenoquine efficacy in *Plasmodium vivax* malaria phase 3 clinical trials, **Pamela St. Jean**, PAREXEL International Corp, USA, MMV co-author: Stephan Duparc
- 1736 Haemoglobin decline in G6PD normal *P. vivax* patients treated with chloroquine and tafenoquine or primaquine in the phase 3 TAF112582 (DETECTIVE) study, **Khadeeja Mohamed**, GlaxoSmithKline, UK, MMV co-author: Stephan Duparc
- 1812 Health worker's post-training practices for case management of severe malaria in southern Nigeria, **Olatunde M. Adesoro**, Malaria Consortium, Nigeria, MMV co-author: Alexis Kamdjou

